SCHEMBL5224874

SCHEMBL5224874

COC(=O)CN(Cc1ccc(OCc2ccccc2)cc1)S(=O)(=O)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
PTPN1 P18031 2/20 0.51
MAPT P10636 2/20 0.48
HPGD P15428 2/20 0.46
CYP2C9 P11712 1/20 0.46
EGFR P00533 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ADAM33 Q9BZ11 1/20 0.45
EPHX2 P34913 1/20 0.45
ALOX5 P09917 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
MMP1 P03956 1/20 0.44
MMP13 P45452 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
MAOB P27338 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN6 P29350 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225058 0.91 ALDH1A1 (0.54) ALDH1A1PTPN1SMN1; SMN2ALOX5PTGS1
SCHEMBL5434168 0.89 ALDH1A1 (0.53) ALDH1A1PTPN1MAPTHPGDSMN1; SMN2
SCHEMBL5313019 0.85 ALDH1A1 (0.44) ALDH1A1MAPTSMN1; SMN2
SCHEMBL4671174 0.80 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL5228366 0.79 PPARG (0.51) ALDH1A1MAPTCYP2C9SMN1; SMN2
SCHEMBL5225924 0.75 TAS2R14 (0.40) ALDH1A1PTPN1
SCHEMBL5435181 0.73 TAS2R14 (0.39) ALDH1A1PTPN1SMN1; SMN2L3MBTL1PTPN6
SCHEMBL5225370 0.71 PPARG (0.52) MAPTCYP2C9
SCHEMBL5223943 0.71 PPARG (0.58) MAPTCYP2C9
SCHEMBL5226093 0.71 MEN1 (0.43) ALDH1A1MAPTSMN1; SMN2ALOX5PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 ALDH1A1 1086/4885PTPN1 1365/4885MAPT 3705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.